Stefan Wiefarn1, Christian Heumann2, Anja Rettelbach3, Karel Kostev4. 1. 1 Business Analytics, MSD Sharp und Dohme, Haar, Germany. 2. 2 Institut für Statistik, Ludwig-Maximilians-Universität München, Munich, Germany. 3. 3 Primary Care, MSD Sharp und Dohme, Haar, Germany. 4. 4 Epidemiology, IMS Health, Frankfurt, Germany.
Abstract
OBJECTIVE: The present retrospective study examines the influence of disease management programs on nonfatal stroke in type 2 diabetes mellitus (T2DM) patients in Germany. METHODS: The evaluation is based on retrospective patient data from the Disease Analyzer (IMS Health). The analysis included 169 414 T2DM patients aged 40 years and older with an initial prescription of antihyperglycemic therapy between January 2004 and December 2014. A total of 86 713 patients participated in a disease management program (DMP) for T2DM and 82 701 patients received standard care. The main outcome measure of this study was nonfatal stroke. Kaplan-Meier curves of DMP and SC patients were compared using log rank test. The Cox proportional hazards model was used to provide an adjusted estimate of the DMP effect. RESULTS: It is apparent from the baseline characteristics that the general health of patients receiving standard care was poorer than that of patients participating in a DMP. The baseline HbA1c value was 7.6% in the DMP group and 7.8% in the SC group. Furthermore, the SC group had a higher proportion of preexisting conditions, such as coronary heart disease (CHD), peripheral arterial occlusive disease (pAOD), and renal insufficiency. The proportion of patients who received insulin in first year therapy was higher in the SC group. Time to event analysis showed that DMP was associated with a delayed occurrence of stroke, because stroke occurred an average of 350 days later in DMP patients than in patients receiving SC (DMP: 1.216 days, RV: 866 days). The Cox model with covariable adjustment confirmed the significant association of DMPs with nonfatal stroke in patients with type 2 diabetes mellitus (HR 0.71; 95% CI: 0.69-0.74). CONCLUSION: The present study indicates that DMPs are positively associated with stroke. The possible reasons for this must be verified in further studies.
OBJECTIVE: The present retrospective study examines the influence of disease management programs on nonfatal stroke in type 2 diabetes mellitus (T2DM) patients in Germany. METHODS: The evaluation is based on retrospective patient data from the Disease Analyzer (IMS Health). The analysis included 169 414 T2DM patients aged 40 years and older with an initial prescription of antihyperglycemic therapy between January 2004 and December 2014. A total of 86 713 patients participated in a disease management program (DMP) for T2DM and 82 701 patients received standard care. The main outcome measure of this study was nonfatal stroke. Kaplan-Meier curves of DMP and SC patients were compared using log rank test. The Cox proportional hazards model was used to provide an adjusted estimate of the DMP effect. RESULTS: It is apparent from the baseline characteristics that the general health of patients receiving standard care was poorer than that of patients participating in a DMP. The baseline HbA1c value was 7.6% in the DMP group and 7.8% in the SC group. Furthermore, the SC group had a higher proportion of preexisting conditions, such as coronary heart disease (CHD), peripheral arterial occlusive disease (pAOD), and renal insufficiency. The proportion of patients who received insulin in first year therapy was higher in the SC group. Time to event analysis showed that DMP was associated with a delayed occurrence of stroke, because stroke occurred an average of 350 days later in DMPpatients than in patients receiving SC (DMP: 1.216 days, RV: 866 days). The Cox model with covariable adjustment confirmed the significant association of DMPs with nonfatal stroke in patients with type 2 diabetes mellitus (HR 0.71; 95% CI: 0.69-0.74). CONCLUSION: The present study indicates that DMPs are positively associated with stroke. The possible reasons for this must be verified in further studies.
Authors: Roland Linder; D Horenkamp-Sonntag; B Bestmann; U Battmer; T Heilmann; F Verheyen Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2015-04 Impact factor: 1.513
Authors: Louis Jacob; Peyman Hadji; Ute-Susann Albert; Matthias Kalder; Karel Kostev Journal: Breast Cancer Res Treat Date: 2015-08-12 Impact factor: 4.872